What did BMO change in the March 18, 2026 note on HQY analyst rating?

BMO Capital maintained a **Market Perform** rating on March 18, 2026, while raising its FY27 outlook. The note did not include a new price target. This signals cautious optimism rather than a clear upgrade or downgrade

How should investors interpret a maintained Market Perform for HQY?

A maintained Market Perform means expected returns should track the market and peers. Investors should hold and monitor execution on FY27 guidance. It is not a buy or sell directive in isolation

Does the BMO note include an HQY price target change?

No. The March 18, 2026 BMO commentary raised FY27 outlooks but did not publish a new HQY price target. Lack of a price target limits valuation clarity for short‑term trading

How reliable is the Meyka grade for HQY in light of the analyst action?

Meyka AI rates HQY with a grade of **A** based on multiple inputs, including analyst consensus. The grade complements the HQY analyst rating but is not a guarantee. It should be one input among many for investors

Analyst Ratings

BMO Maintains Market Perform on HealthEquity (HQY) March 18, 2026

ByHuzaifa Zahoor March 19, 2026March 19, 2026

BMO Capital maintained a Market Perform rating on HealthEquity, Inc. (HQY) on March 18, 2026, a clear signal that near-term expectations are steady rather than bullish. The HQY analyst rating note arrives with a raised FY27 outlook, according to the analyst write-up, but no new price target was published. The market reaction was muted, with the stock moving 0.05% ($0.04) at the time of the note. Meyka AI rates HQY with a grade of A and factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus